Anyone used the 2% pyrilutamide / KX-826 from anagenica or anywhere else?
    Product 1/15/2025

    From the encyclopedia
    Minoxidil →

    Vasodilator used on the scalp and, at low doses, as a tablet

    Alfatradiol →

    Weak form of estrogen applied to the scalp

    Pyrilutamide →

    Experimental topical anti-androgen, also known as KX-826

    At a glance
    In this question or advice post, the primary subjects mentioned are
    💧 Minoxidil (topical) 5% 3 weeks
    💧 Minoxidil (topical) 2% 3 weeks
    💧 Alfatradiol (topical) 0.1% 3 months
    💧 Alfatradiol + Bimatoprost (topical) 0.1% 1 month
    💧 Dutasteride (topical)
    the tone is 😐 neutral.

    Other terms

    People are discussing hair loss treatments, including pyrilutamide, minoxidil, dutasteride, alfatradiol, and bimatoprost. Users share their experiences and side effects, noting that pyrilutamide is considered more effective and safer than RU58841.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community KX-826 and RU58841: do topical anti-androgens work?

       10 upvotes 3 weeks ago
      KX-826 and RU58841 are topical anti-androgens discussed for hair loss prevention, with KX-826 showing promise in trials and RU58841 having mixed anecdotal results. Users report combining these with treatments like minoxidil, finasteride, and dutasteride, with varying success and concerns about side effects.

      community Before and after adding pyrilutamide and alfatrodial

       67 upvotes 5 months ago
      A user shared their experience with hair loss treatments, using minoxidil, pyrilutamide, alfatrodial, and nizoral to improve hair density and thickness. They reported positive results without side effects and emphasized the importance of consistency with topical treatments.

      community KX-826 Phase 3 Results Are Out

       121 upvotes 6 months ago
      KX-826 shows promising results for hair growth with fewer side effects, offering an alternative to finasteride and minoxidil. Users discuss combining it with minoxidil, dermarolling, and Nizoral for improved results.

      community Any treatment not nuking systemic DHT levels?

       16 upvotes 7 months ago
      Hair loss treatments that avoid significantly lowering systemic DHT levels, focusing on topical options like dutasteride mesotherapy, minoxidil, and ketoconazole. The user is exploring alternatives like KX-826 and RU58841 due to concerns about hormone levels.

    Related Research

    6 / 6 results

      research Androgenetic Alopecia: Therapy Update

      May 2023 in “Drugs”
      This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

      research The 100 most cited articles in androgenetic alopecia: A bibliometric analysis

      March 2025 in “Medicine”
      This study performed a bibliometric analysis of the 100 most cited articles on androgenetic alopecia from 1975 to 2024, revealing that U.S. authors contributed most and highlighting a trend toward research focused on treatment options, especially between 2020 and 2024.

      research A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies

      December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology”
      This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.